Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Cash & Equivalents (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of Cash & Equivalents data on record, last reported at $4.6 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 59.05% year-over-year to $4.6 million; the TTM value through Sep 2025 reached $4.6 million, up 59.05%, while the annual FY2024 figure was $3.2 million, 57.31% down from the prior year.
  • Cash & Equivalents reached $4.6 million in Q3 2025 per CYCN's latest filing, up from $3.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $70.4 million in Q2 2021 and bottomed at $2.9 million in Q3 2024.
  • Average Cash & Equivalents over 5 years is $20.6 million, with a median of $7.6 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: plummeted 82.56% in 2023, then soared 59.05% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $54.0 million in 2021, then tumbled by 75.2% to $13.4 million in 2022, then tumbled by 43.42% to $7.6 million in 2023, then plummeted by 57.31% to $3.2 million in 2024, then surged by 41.34% to $4.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $4.6 million in Q3 2025, $3.0 million in Q2 2025, and $3.6 million in Q1 2025.